Corazon D. Sanders, serving as a director at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), completed a transaction disposing of 2,000 shares of the firm's common equity on June 15, 2026. The sale generated total proceeds of $50,100, executed at a per-share price of $25.05. This disposition represents a direct reduction in her ownership stake, leaving her with a remaining direct holding of 21,095 shares of Ultragenyx common stock. The reported figure encompasses shares underlying Restricted Stock Units (RSUs) previously granted to Ms. Sanders, which remain subject to established vesting conditions.
The insider sale unfolds within a period of divergent corporate developments for the biotechnology firm. Ultragenyx recently disclosed its financial performance for the first quarter of 2026, revealing a net loss of $1.84 per share. This result exceeded analyst consensus expectations of a $1.46 loss per share. Top-line revenue also fell short of forecasts, posting $136 million against a projected $160.69 million. Despite these financial misses, management reaffirmed its full-year revenue guidance, signaling continuity in long-term projections.
In a contrasting development, Cantor Fitzgerald adjusted its valuation outlook for Ultragenyx shares, raising the price target from $84 to $96 while maintaining an Overweight rating. The analyst firm cited an increased probability of success for GTX-102, a therapeutic candidate targeting Angelman syndrome, following two months of clinical research data. This upgrade suggests growing institutional confidence in the company's pipeline, despite near-term financial headwinds.
Corporate governance updates also marked this period. Ultragenyx concluded its annual shareholder meeting, where investors approved the election of three Class I directors to the board. Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch were elected to serve until the 2029 annual meeting. These governance changes coincide with the ongoing evaluation of the company's financial trajectory and clinical progress.